NAMS Menopause Certification Exam – Complete 50 Questions
and Solutions Actual Exam 2026/2027: Complete Exam-Style
Questions with Detailed Rationales | 100% Verified | Pass
Guaranteed – A+ Graded
Time Limit: 120 minutes
1. A 52-year-old woman reports she has not had a menstrual period in 14 months.
According to the STRAW+10 staging system, what is her menopausal status?
A) Late perimenopause
B) Early postmenopause ✓
C) Early perimenopause
D) Premenopause
Correct Answer: B) Early postmenopause
Rationale: STRAW+10 defines postmenopause as beginning 12 months after the final
menstrual period; a 14-month amenorrhea confirms early postmenopause.
2. Which term is the currently accepted nomenclature for the collection of
vulvovaginal and urinary symptoms associated with estrogen deficiency after
menopause?
A) Atrophic vaginitis
B) Vulvovaginal atrophy
C) Genitourinary syndrome of menopause ✓
D) Urogenital aging
Correct Answer: C) Genitourinary syndrome of menopause
Rationale: NAMS and ISSWSH endorse the term genitourinary syndrome of menopause
(GSM) to encompass vulvovaginal atrophy and urinary symptoms.
, 3. A 48-year-old woman with irregular menses and bothersome hot flashes has a
serum FSH level of 18 IU/L measured on day 3 of her cycle. Which interpretation
is most consistent with current guidelines?
A) The elevated FSH definitively confirms menopause
B) The FSH level is normal and excludes perimenopause
C) A single FSH measurement is unreliable for diagnosing perimenopause due to
hormonal fluctuation ✓
D) FSH levels must be measured weekly for one month to establish the diagnosis
Correct Answer: C) A single FSH measurement is unreliable for diagnosing
perimenopause due to hormonal fluctuation
Rationale: FSH levels fluctuate significantly during the menopausal transition; clinical
presentation and menstrual history are more reliable than an isolated FSH value.
4. A 58-year-old woman with obesity and a history of deep vein thrombosis asks
about systemic menopausal hormone therapy for severe vasomotor symptoms.
Which formulation is associated with the lowest risk of venous
thromboembolism?
A) Oral conjugated equine estrogens
B) Oral 17-beta estradiol
C) Transdermal 17-beta estradiol ✓
D) Oral esterified estrogens
Correct Answer: C) Transdermal 17-beta estradiol
Rationale: Transdermal estradiol bypasses hepatic first-pass metabolism, resulting in
minimal impact on hepatic coagulation protein synthesis and a lower VTE risk
compared with oral estrogen.
5. Which of the following are absolute contraindications to systemic menopausal
hormone therapy? (Select all that apply.)
A) History of breast cancer
B) Active or prior venous thromboembolism
C) Known liver disease
D) Unexplained vaginal bleeding
E) History of osteoporosis
, Correct Answers: A, B, C, D
Rationale: Active or past breast cancer, VTE, severe liver disease, and unexplained
vaginal bleeding are absolute contraindications to systemic MHT; osteoporosis is an
indication, not a contraindication.
6. Menopause is clinically defined as:
A) The cessation of ovarian function due to surgical removal of ovaries only
B) 6 months of amenorrhea in a woman over age 45
C) 12 consecutive months of amenorrhea without other pathologic cause ✓
D) A serum FSH level greater than 30 IU/L on two occasions
Correct Answer: C) 12 consecutive months of amenorrhea without other pathologic
cause
Rationale: The clinical diagnosis of natural menopause requires 12 months of
spontaneous amenorrhea in the absence of pathologic or physiologic causes.
7. Arrange the following steps in the recommended initial evaluation of a woman
presenting with menopausal symptoms.
A) Assess for cardiovascular and metabolic risk factors
B) Obtain a detailed menstrual and symptom history
C) Evaluate for contraindications to menopausal hormone therapy
D) Determine menopausal stage using age and menstrual history
Correct Order: B, D, A, C
Rationale: The evaluation begins with a comprehensive history, followed by menopausal
staging, cardiovascular risk assessment, and finally screening for MHT
contraindications.
8. Fezolinetant, approved for moderate to severe vasomotor symptoms, exerts its
therapeutic effect primarily through which mechanism?
A) Selective estrogen receptor modulation
B) Serotonin reuptake inhibition
C) Neurokinin-3 receptor antagonism ✓
D) Gamma-aminobutyric acid receptor agonism
and Solutions Actual Exam 2026/2027: Complete Exam-Style
Questions with Detailed Rationales | 100% Verified | Pass
Guaranteed – A+ Graded
Time Limit: 120 minutes
1. A 52-year-old woman reports she has not had a menstrual period in 14 months.
According to the STRAW+10 staging system, what is her menopausal status?
A) Late perimenopause
B) Early postmenopause ✓
C) Early perimenopause
D) Premenopause
Correct Answer: B) Early postmenopause
Rationale: STRAW+10 defines postmenopause as beginning 12 months after the final
menstrual period; a 14-month amenorrhea confirms early postmenopause.
2. Which term is the currently accepted nomenclature for the collection of
vulvovaginal and urinary symptoms associated with estrogen deficiency after
menopause?
A) Atrophic vaginitis
B) Vulvovaginal atrophy
C) Genitourinary syndrome of menopause ✓
D) Urogenital aging
Correct Answer: C) Genitourinary syndrome of menopause
Rationale: NAMS and ISSWSH endorse the term genitourinary syndrome of menopause
(GSM) to encompass vulvovaginal atrophy and urinary symptoms.
, 3. A 48-year-old woman with irregular menses and bothersome hot flashes has a
serum FSH level of 18 IU/L measured on day 3 of her cycle. Which interpretation
is most consistent with current guidelines?
A) The elevated FSH definitively confirms menopause
B) The FSH level is normal and excludes perimenopause
C) A single FSH measurement is unreliable for diagnosing perimenopause due to
hormonal fluctuation ✓
D) FSH levels must be measured weekly for one month to establish the diagnosis
Correct Answer: C) A single FSH measurement is unreliable for diagnosing
perimenopause due to hormonal fluctuation
Rationale: FSH levels fluctuate significantly during the menopausal transition; clinical
presentation and menstrual history are more reliable than an isolated FSH value.
4. A 58-year-old woman with obesity and a history of deep vein thrombosis asks
about systemic menopausal hormone therapy for severe vasomotor symptoms.
Which formulation is associated with the lowest risk of venous
thromboembolism?
A) Oral conjugated equine estrogens
B) Oral 17-beta estradiol
C) Transdermal 17-beta estradiol ✓
D) Oral esterified estrogens
Correct Answer: C) Transdermal 17-beta estradiol
Rationale: Transdermal estradiol bypasses hepatic first-pass metabolism, resulting in
minimal impact on hepatic coagulation protein synthesis and a lower VTE risk
compared with oral estrogen.
5. Which of the following are absolute contraindications to systemic menopausal
hormone therapy? (Select all that apply.)
A) History of breast cancer
B) Active or prior venous thromboembolism
C) Known liver disease
D) Unexplained vaginal bleeding
E) History of osteoporosis
, Correct Answers: A, B, C, D
Rationale: Active or past breast cancer, VTE, severe liver disease, and unexplained
vaginal bleeding are absolute contraindications to systemic MHT; osteoporosis is an
indication, not a contraindication.
6. Menopause is clinically defined as:
A) The cessation of ovarian function due to surgical removal of ovaries only
B) 6 months of amenorrhea in a woman over age 45
C) 12 consecutive months of amenorrhea without other pathologic cause ✓
D) A serum FSH level greater than 30 IU/L on two occasions
Correct Answer: C) 12 consecutive months of amenorrhea without other pathologic
cause
Rationale: The clinical diagnosis of natural menopause requires 12 months of
spontaneous amenorrhea in the absence of pathologic or physiologic causes.
7. Arrange the following steps in the recommended initial evaluation of a woman
presenting with menopausal symptoms.
A) Assess for cardiovascular and metabolic risk factors
B) Obtain a detailed menstrual and symptom history
C) Evaluate for contraindications to menopausal hormone therapy
D) Determine menopausal stage using age and menstrual history
Correct Order: B, D, A, C
Rationale: The evaluation begins with a comprehensive history, followed by menopausal
staging, cardiovascular risk assessment, and finally screening for MHT
contraindications.
8. Fezolinetant, approved for moderate to severe vasomotor symptoms, exerts its
therapeutic effect primarily through which mechanism?
A) Selective estrogen receptor modulation
B) Serotonin reuptake inhibition
C) Neurokinin-3 receptor antagonism ✓
D) Gamma-aminobutyric acid receptor agonism
